Tags

Type your tag names separated by a space and hit enter

Rimonabant: a selective blocker of the cannabinoid CB1 receptors for the management of obesity, smoking cessation and cardiometabolic risk factors.
Expert Opin Investig Drugs. 2006 Mar; 15(3):307-15.EO

Abstract

Rimonabant is the first selective blocker of the cannabinoid CB1 receptors being developed for the treatment of obesity, tobacco smoking and cardiometabolic risk factors. Following 1 year of treatment, rimonabant 20 mg/day leads to greater weight loss compared with placebo. Therapy with rimonabant is also associated with favourable changes in serum lipids and an improvement in glycaemic control in Type 2 diabetics. At the same dose, rimonabant significantly increases the cigarette smoking quit rates compared with placebo. Rimonabant appears to be generally well tolerated, with primary side effects of mild nausea, diarrhoea, anxiety and depression. As an agent with a novel mechanism of action, rimonabant has the potential to be a useful adjunct to lifestyle modification in the treatment of obesity, metabolic syndrome and cigarette smoking.

Authors+Show Affiliations

Division of Cardiology/Baker 4, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA. egelfand@bidmc.harvard.eduNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

16503766

Citation

Gelfand, Eli V., and Christopher P. Cannon. "Rimonabant: a Selective Blocker of the Cannabinoid CB1 Receptors for the Management of Obesity, Smoking Cessation and Cardiometabolic Risk Factors." Expert Opinion On Investigational Drugs, vol. 15, no. 3, 2006, pp. 307-15.
Gelfand EV, Cannon CP. Rimonabant: a selective blocker of the cannabinoid CB1 receptors for the management of obesity, smoking cessation and cardiometabolic risk factors. Expert Opin Investig Drugs. 2006;15(3):307-15.
Gelfand, E. V., & Cannon, C. P. (2006). Rimonabant: a selective blocker of the cannabinoid CB1 receptors for the management of obesity, smoking cessation and cardiometabolic risk factors. Expert Opinion On Investigational Drugs, 15(3), 307-15.
Gelfand EV, Cannon CP. Rimonabant: a Selective Blocker of the Cannabinoid CB1 Receptors for the Management of Obesity, Smoking Cessation and Cardiometabolic Risk Factors. Expert Opin Investig Drugs. 2006;15(3):307-15. PubMed PMID: 16503766.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Rimonabant: a selective blocker of the cannabinoid CB1 receptors for the management of obesity, smoking cessation and cardiometabolic risk factors. AU - Gelfand,Eli V, AU - Cannon,Christopher P, PY - 2006/3/1/pubmed PY - 2006/4/28/medline PY - 2006/3/1/entrez SP - 307 EP - 15 JF - Expert opinion on investigational drugs JO - Expert Opin Investig Drugs VL - 15 IS - 3 N2 - Rimonabant is the first selective blocker of the cannabinoid CB1 receptors being developed for the treatment of obesity, tobacco smoking and cardiometabolic risk factors. Following 1 year of treatment, rimonabant 20 mg/day leads to greater weight loss compared with placebo. Therapy with rimonabant is also associated with favourable changes in serum lipids and an improvement in glycaemic control in Type 2 diabetics. At the same dose, rimonabant significantly increases the cigarette smoking quit rates compared with placebo. Rimonabant appears to be generally well tolerated, with primary side effects of mild nausea, diarrhoea, anxiety and depression. As an agent with a novel mechanism of action, rimonabant has the potential to be a useful adjunct to lifestyle modification in the treatment of obesity, metabolic syndrome and cigarette smoking. SN - 1744-7658 UR - https://www.unboundmedicine.com/medline/citation/16503766/Rimonabant:_a_selective_blocker_of_the_cannabinoid_CB1_receptors_for_the_management_of_obesity_smoking_cessation_and_cardiometabolic_risk_factors_ L2 - https://www.tandfonline.com/doi/full/10.1517/13543784.15.3.307 DB - PRIME DP - Unbound Medicine ER -